Please assess the completion status of the following clinical trial:

Trial Title: MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the screening procedures and in the opinion of the PI complies with all the requirements of the study.~* Subject is healthy, determined at the screening medical evaluation (including but not limited to medical history, physical examination and clinical laboratory evaluations).~* Subject is Caucasian.~* Female subject must be of non-childbearing potential (surgically sterile \[hysterectomy or bilateral tubal ligation\] or post-menopausal ≥ 1 year with follicle stimulating hormone \[FSH\] \> 40 U/L). Women receiving hormone replacement therapy (HRT) are eligible to enroll.~* Male subject must agree to use condoms and refrain from sperm donation from Day 1 until 30 days post last dose or have documentation of vasectomy.~* Subject has a body weight \> 50 kg and body mass index (BMI) between 19.5 and 32 kg/m2, inclusive, at screening.~* Subject has no clinically significant abnormal findings related to their systolic or diastolic blood pressure (BP), per the investigator's judgment, at screening or Day 1.~* Subject has no clinically significant abnormal findings in 12 lead ECG, per the investigator's judgment, at screening.~Exclusion Criteria:~* Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s) as determined by the investigator or designee.~* Subject has clinically significant abnormalities on a 12 lead ECG done at screening~* Subject has clinically significant abnormalities on a 48-hour ambulatory ECG done at screening~* Subject has any disorder that would interfere with the absorption, distribution, metabolism, or excretion of drugs.~* Subject has any concurrent disease or condition that, in the opinion of the investigator, would make the subject unsuitable for participation in the clinical study.~* Subject is unlikely to comply with the protocol requirements, instructions, and study related restrictions; e.g., uncooperative attitude, unavailable for follow-up call, and/or improbability of completing the clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 10 mg (Type: EXPERIMENTAL): single oral daily dose of 10 mg N91115 for 14 days
- Placebo (Type: PLACEBO_COMPARATOR): single oral daily dose of placebo for 14 days
- 50 mg (Type: EXPERIMENTAL): single oral daily dose of 50 mg N91115 for 14 days
- 50 mg (single dose) (Type: EXPERIMENTAL): single oral dose of 50 mg N91115
- 250 mg (Type: EXPERIMENTAL): single oral daily dose of 250 mg N91115 for 14 days (fasted)
- 250 mg (Fed) (Type: EXPERIMENTAL): single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
- 500 mg (Type: EXPERIMENTAL): single oral daily dose of 500 mg N91115 for 14 days
- Placebo-Day 1 only (Type: PLACEBO_COMPARATOR): Single oral dose of placebo (Day 1 only)

Based on this trial design, predict the completion outcome and termination type (if applicable).